New York, NY June 26, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, received a letter from the New York Stock Exchange informing Michael Feldschuh, President and Chief Executive Officer of Daxor Corporation, that the Company is “Back in compliance with the NYSE MKT LLC continued listing standards set forth in Part 10 of the NYSE MKT Company Guide.” Specifically, the Company has resolved the continued listing deficiency with respect to Sections 134 and 1101 of the Company Guide referenced in the Exchange’s letter dated March 29, 2017 since it filed its Form N-CSR for the fiscal year ended December 31, 2016 with the Securities and Exchange Commission on March 27, 2017.
The late filer (LF) indicator is no longer disseminated beginning at the opening of trading (as of May 1, 2017) and the Company has been removed from the lost of NYSE MKT noncompliant issuers on the Exchange’s website.
Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor’s single use diagnostic kit. For more information regarding Daxor Corporation’s Blood Volume Analyzer BVA-100, visit Daxor’s website at www.Daxor.com.
Daxor Contact Information: John Wilkens, Chief Financial Officer, email@example.com.